Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
202.38 x 100 204.77 x 100
Post-market by (Cboe BZX)
205.29 +2.57 (+1.27%) 03/28/25 [NYSE]
202.38 x 100 204.77 x 100
Post-market 204.00 -1.29 (-0.63%) 17:51 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
201.59
Day High
206.02
Open 202.73
Previous Close 202.72 202.72
Volume 6,478,200 6,478,200
Avg Vol 6,860,260 6,860,260
Stochastic %K 31.14% 31.14%
Weighted Alpha +22.85 +22.85
5-Day Change -4.72 (-2.25%) -4.72 (-2.25%)
52-Week Range 153.58 - 218.66 153.58 - 218.66
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 363,153,472
  • Shares Outstanding, K 1,768,978
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,130 M
  • EBITDA $ 17,516 M
  • 60-Month Beta 0.61
  • Price/Sales 6.37
  • Price/Cash Flow 13.48
  • Price/Book 105.75

Options Overview Details

View History
  • Implied Volatility 27.22% ( +2.69%)
  • Historical Volatility 19.68%
  • IV Percentile 90%
  • IV Rank 77.61%
  • IV High 30.36% on 10/29/24
  • IV Low 16.36% on 05/10/24
  • Put/Call Vol Ratio 0.51
  • Today's Volume 34,877
  • Volume Avg (30-Day) 24,924
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 375,459
  • Open Int (30-Day) 364,723

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.51
  • Number of Estimates 9
  • High Estimate 2.61
  • Low Estimate 2.48
  • Prior Year 2.31
  • Growth Rate Est. (year over year) +8.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
196.49 +4.48%
on 03/26/25
Period Open: 209.03
218.66 -6.11%
on 03/10/25
-3.74 (-1.79%)
since 02/28/25
3-Month
168.06 +22.15%
on 01/22/25
Period Open: 178.01
218.66 -6.11%
on 03/10/25
+27.28 (+15.32%)
since 12/27/24
52-Week
153.58 +33.67%
on 05/30/24
Period Open: 182.10
218.66 -6.11%
on 03/10/25
+23.19 (+12.73%)
since 03/28/24

Most Recent Stories

More News
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?

Following the crowd has been disparaged quite a bit in the past. But sometimes the crowd knows what it's doing. Going in the same direction in those cases is wise.

VHT : 262.90 (-0.47%)
CVX : 166.09 (-0.34%)
CEG : 205.39 (-1.82%)
COP : 102.37 (-0.44%)
JNJ : 163.71 (+0.36%)
ABBV : 205.29 (+1.27%)
AEP : 106.96 (+1.72%)
WMB : 59.19 (-0.40%)
UNH : 516.04 (+0.06%)
NEE : 70.45 (+0.60%)
ABT : 130.82 (-0.40%)
VDE : 128.40 (-0.48%)
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income

Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list. Still, some companies are doing just fine amid the volatility, including AbbVie...

ABT : 130.82 (-0.40%)
ABBV : 205.29 (+1.27%)
3 Healthcare Stocks in the Doghouse

3 Healthcare Stocks in the Doghouse

BLCO : 14.13 (-5.80%)
IRTC : 105.00 (-1.05%)
ABBV : 205.29 (+1.27%)
5 Large Drug Stocks to Watch as Industry Recovers

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large drugmakers and...

BAYRY : 6.1435 (+0.06%)
NVO : 69.30 (-1.23%)
NVS : 112.57 (+1.05%)
ABBV : 205.29 (+1.27%)
PFE : 25.21 (+0.80%)
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

SRPT : 70.41 (-1.95%)
BMRN : 71.44 (-1.91%)
ABBV : 205.29 (+1.27%)
MRNA : 31.12 (-3.11%)
BIIB : 138.37 (-1.40%)
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

GCTK : 0.2050 (-11.75%)
TCBP : 0.5000 (-67.53%)
ABBV : 205.29 (+1.27%)
ATNM : 1.8100 (-4.23%)
RGC : 25.67 (-26.38%)
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock

NVO : 69.30 (-1.23%)
LLY : 822.51 (+0.10%)
ABBV : 205.29 (+1.27%)
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease...

JNJ : 163.71 (+0.36%)
MRK : 89.23 (+1.86%)
LLY : 822.51 (+0.10%)
ABBV : 205.29 (+1.27%)
Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends

So, you want to invest in AbbVie (NYSE: ABBV) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy? The...

ABBV : 205.29 (+1.27%)
3 Dividend Stocks to Buy for Reliable Passive Income

You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of Retirement and Disability Policy says Social Security's funds might run out by 2037,...

CVX : 166.09 (-0.34%)
ABBV : 205.29 (+1.27%)
PFE : 25.21 (+0.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 211.44
2nd Resistance Point 208.73
1st Resistance Point 207.01
Last Price 205.29
1st Support Level 202.58
2nd Support Level 199.87
3rd Support Level 198.15

See More

52-Week High 218.66
Last Price 205.29
Fibonacci 61.8% 193.80
Fibonacci 50% 186.12
Fibonacci 38.2% 178.44
52-Week Low 153.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies